New mRNA vaccine could stop lyme disease in its tracks

NCT ID NCT07561294

Ongoing ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests an experimental mRNA vaccine (mRNA-1982) designed to prevent Lyme disease, which is spread by tick bites. About 350 healthy adults aged 18 to 70 will receive either the vaccine or a placebo to check for safety and immune response. The goal is to find the best dose that triggers strong protection against the bacteria that causes Lyme disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYME DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lyme disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYME DISEASE

Contacts and locations

Locations

Bluewater Clinical Research Group Inc.

Sarnia, Ontario, N7T 4X3, Canada
Colchester Research Group

Truro, Nova Scotia, B2N 1L2, Canada
Diex Recherche Inc. - Division Joliette

Joliette, Quebec, J6E 6A9, Canada
Diex Recherche Inc. - Division Quebec

Québec, G1V 4T3, Canada
Diex Recherche Inc. - Division Sherbrooke

Sherbrooke, Quebec, J1L 0H8, Canada
Diex Recherche Inc. - Division Victoriaville

Victoriaville, Quebec, G6P 3Z8, Canada
Dr. Anil K. Gupta Medicine Professional Corporation Inc.

Toronto, Ontario, M9V 4B4, Canada
Stouffville Medical Research Institute Inc.

Stouffville, Ontario, L4A 1H2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.